A passion for
patient care with


When treating both respiratory and non-respiratory disease, even dispersion of inhaled therapeutics throughout the lung is a critical factor driving efficacy and safety.

Comparison 1

Conventional dry powder technologies
rely on the use of lactose blending or
low-density particles to facilitate

Comparison 3

To optimize dispersion of therapeutic particles,
the scientists and engineers at PULMATRiX have
developed a technological innovation, iSPERSE.

iSPERSE makes possible a new generation of pulmonary-delivered
therapies to dramatically improve patient outcomes.

Our mission

PULMATRiX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system.

Learn about our pipeline


iSPERSE™ is a scalable platform, with application across drug classes and dry-powder delivery devices. This creates broad potential for pipeline development and strategic partnership.

  • Partnering with Cipla on PUR1900 anti-fungal program in Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Cipla is India’s 2nd largest pharmaceutical company with global presence in over 130 countries, over 35 manufacturing facilities, and a vast network for direct commercialization and strategic alliances
  • Our partnership validates the PUR1900 development plan and the potential of iSPERSE™
    PUR1900 (itraconazole formulated with iSPERSE™) provided about 50-fold higher lung exposure and 85-fold lower plasma exposure than Sporanox, the currently available oral formulation of itraconazole, at one tenth the dose. PUR1900 has the potential to address the underlying cause of disease and avoid the side effects of oral therapy

Learn more about PUR1900

To inquire about partnering with PULMATRiX, e-mail us at bd@pulmatrix.com.



Small, dense, and dispersible particles for highly efficient delivery of respiratory and non-respiratory therapies via the respiratory system

Explore iSPERSE